Dhingra Sadhna, Li Wei, Tan Dongfeng, Zenali Maryam, Zhang Haizeng, Brown Robert E
Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center-Medical School at Houston, Houston, Texas 77030, USA
Int J Clin Exp Pathol. 2010 Nov 2;3(8):792-7.
fibrolamellar hepatocellular carcinoma (FLHCC) has a better prognosis than conventional hepatocellular carcinoma. Nevertheless, FLHCC has a propensity to recur with limited responsiveness to chemotherapy.
The purpose of this study was to provide insight into the cell cycle biology of FLHCC, as it relates to FLHCC's relatively indolent nature and lack of chemoresponsiveness.
in seven cases of FLHCC, we assessed: 1. immunoexpression of protein analytes indicating cell cycle progression including Ki-67 (G1, S, G2 and M phases) and S-phase kinase-associated protein (Skp) 2 along with the mitotic index (MI); 2.immunoreactivity for cyclin-dependent kinase inhibitors of cell cycle progression from G1 to S phase, p27Kip1 and p16INK4.
the mean percentage of Ki-67 nuclear positivity in neoplastic hepatocytes ranged from 1.0% to 29.7%. Nuclear Skp2 immunoexpression was not observed in any of the cases. The mitotic index was very low (0-1 mitotic figure / 10 high-power fields). All cases showed moderate to strong nuclear p16INK4 positivity (diffuse in five and focal in two). Contras-tively, the adjacent non-neoplastic hepatocytes expressed only mild (2 cases) to no (3 cases) p16INK4.
our analysis has revealed that cell cycle arrest in FLHCC occurs in G0G1 phase and is associated with overexpression of the cell cycle regulator, p16INK4 in tumoral cell nuclei compared with non-neoplastic hepatocytes. In conjunction with our previous immunohistochemical demonstration of a constitutively activated nuclear factor (NF)-kappaB pathway and stemness characteristics of FLHCC with limited differentiation, this cell cycle arrest elucidates the biology of FLHCC's indolent nature and relative chemoresistance.
纤维板层型肝细胞癌(FLHCC)的预后比传统肝细胞癌更好。然而,FLHCC有复发倾向,且对化疗反应有限。
本研究旨在深入了解FLHCC的细胞周期生物学,因为它与FLHCC相对惰性的本质和缺乏化疗反应性有关。
在7例FLHCC中,我们评估了:1. 指示细胞周期进程的蛋白质分析物的免疫表达,包括Ki-67(G1、S、G2和M期)和S期激酶相关蛋白(Skp)2以及有丝分裂指数(MI);2. 从G1期到S期的细胞周期进程中细胞周期蛋白依赖性激酶抑制剂p27Kip1和p16INK4的免疫反应性。
肿瘤性肝细胞中Ki-67核阳性的平均百分比为1.0%至29.7%。所有病例均未观察到核Skp2免疫表达。有丝分裂指数非常低(0-1个有丝分裂象/10个高倍视野)。所有病例均显示中度至强核p16INK4阳性(5例弥漫性,2例局灶性)。相比之下,相邻的非肿瘤性肝细胞仅表达轻度(2例)至无(3例)p16INK4。
我们的分析表明,FLHCC的细胞周期停滞发生在G0G1期,并且与肿瘤细胞核中细胞周期调节因子p16INK4的过表达有关,与非肿瘤性肝细胞相比。结合我们之前免疫组化证明的持续激活的核因子(NF)-κB途径以及FLHCC分化有限的干性特征,这种细胞周期停滞阐明了FLHCC惰性本质和相对化疗耐药性的生物学机制。